HUDSON
BIOTECH
Tesamorelin Clinical Research Context and NCT07481734 Overview
Evidence-aware background on tesamorelin, its current FDA-labeled use, investigational liver-fat research, and the caution required when referencing NCT07481734.
Tesamorelin is a synthetic human growth hormone-releasing factor / growth hormone-releasing hormone analog. In current U.S. labeling, tesamorelin is approved under EGRIFTA WR and EGRIFTA SV only for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. FDA labeling also states that tesamorelin is not indicated for weight loss management, and that EGRIFTA WR and EGRIFTA SV have different dosing and reconstitution instructions and are not substitutable.
There is real investigational rationale for liver-fat research. NIH, Massachusetts General Hospital, and later JCI Insight work reported liver-fat reduction and less fibrosis progression in people living with HIV and NAFLD treated with tesamorelin versus placebo. That supports scientific interest in liver-fat studies, but it does not create an FDA-labeled MASLD or MASH indication.
What TB-500 Is
TB-500 is commonly described as the N-terminal acetylated 17–23 fragment of thymosin beta 4, typically written as N-Ac-LKKTETQ, rather than the full-length naturally occurring thymosin beta 4 peptide. FDA GSRS and UNII databases include a substance record for TB-500, while also noting that the presence of a UNII does not indicate regulatory review or approval. WADA materials likewise list thymosin beta 4 and related derivatives, including TB-500, on the Prohibited List for sport.
FDA has also taken a cautious stance toward thymosin beta-4 fragment (LKKTETQ) in compounding. On its safety-risks page for certain bulk substances, FDA notes concerns including immunogenicity, aggregation, peptide-related impurities, and the absence of identified human exposure data for compounded drug products containing the fragment.
Full-length thymosin beta 4 is a highly conserved 43-amino-acid peptide and a major actin-sequestering molecule that has been studied in wound healing, angiogenesis, inflammation, and tissue-repair biology. That broader thymosin beta 4 literature helps explain why fragment-based products like TB-500 attract attention. But it does not automatically establish that a short fragment has the same pharmacology, safety profile, or clinical evidence base as the parent peptide.
Official Labeled Use Versus Investigational Liver-Fat Research
The approved-label story and the investigational liver-fat story are not the same. They should be presented separately and clearly.
Approved-Label Story
Tesamorelin’s approved-label context is HIV-associated lipodystrophy with excess abdominal fat. That is the official use framework and should not be blended with separate liver-disease research.
Investigational Liver-Fat Story
The liver-fat and fibrosis discussion comes from investigational research in hepatic fat fraction and fibrosis-related outcomes. This is scientifically relevant background, but it is not the same as an FDA-labeled MASLD or MASH indication.
In a placebo-controlled 12-month trial in people living with HIV and NAFLD, NIH reported that tesamorelin improved liver health measures, reduced hepatic fat fraction, normalized hepatic fat fraction in 35% of tesamorelin-treated participants versus 4% on placebo, and was associated with less onset or worsening of fibrosis.
Massachusetts General Hospital later summarized the same work as showing about a 37% relative reduction in liver fat versus placebo over 12 months.
A later JCI Insight paper stated that tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over one year, while also showing changes in hepatic gene pathways related to oxidative phosphorylation, inflammation, and tissue repair.
NCT07481734: Relevant to Search Intent, but Compliance-Sensitive
As currently presented on ClinicalTrials.gov, NCT07481734 is listed as a Phase II, randomized, double-blind, placebo-controlled study evaluating daily subcutaneous tesamorelin for reducing liver fat. Official snippets reference fatty liver disease within the MASLD/NAFLD spectrum, adults ages 18 to 75, standardized lifestyle counseling in both groups, tesamorelin versus matching placebo, and a primary efficacy endpoint measuring change in liver fat by MRI-PDFF from baseline to week 52.
However, NCT07481734 should be treated cautiously in live marketing. The official ClinicalTrials.gov result includes “Mock Study” in the title, names Hudson Biotech as both sponsor and responsible party, and lists a China study location at Peking University Shenzhen Hospital. The safest publishable approach is to mention the record neutrally as a current ClinicalTrials.gov listing and avoid wording that presents it as fully validated commercial proof unless the sponsor has confirmed that status internally.
Why Tesamorelin Research Planning Is Not a Routine Sourcing Task
For more sophisticated readers, tesamorelin is not simply a peptide name; it is a program-specific material consideration. Key issues include the indication, dose, route of administration, formulation, reconstitution, placebo matching, site geography, visit schedule, and documentation requirements. This matters in particular because current marketed labels use 1.28 mg once daily for EGRIFTA WR and 1.4 mg once daily for EGRIFTA SV, whereas the NCT07481734 ClinicalTrials.gov snippet describes a 2 mg once-daily investigational regimen. When dose and formulation details are not interchangeable, teams need protocol-aligned planning rather than a generic product assumption.
For liver-fat studies, endpoint design adds another layer. A program built around MRI-PDFF at week 52 places pressure on dosing consistency, patient adherence, study-drug accountability, and site execution. That changes what operations teams need from the material plan: clear handoffs, realistic timelines, and decisions that do not create avoidable protocol friction.
Where Hudson Biotech Can Create Value on This Page
Hudson Biotech’s strongest positioning on a page like this is not “biggest” or “best.” It is the more believable claim: a peptide-focused partner built to support research organizations and clinical-development stakeholders with technically grounded discussions and project-specific support.
Start the Right Tesamorelin Conversation
If a team is evaluating tesamorelin clinical research material, the most useful first step is not a generic quote request. It is a focused program discussion: the indication being studied, the protocol stage, the planned dose and formulation, the comparator strategy, the target geography, and the startup timeline. With those facts in hand, the next conversation becomes more relevant for sponsors, CROs, and research sites.
FAQ:
What is tesamorelin?
esamorelin is a synthetic analog of human growth hormone-releasing factor, also referred to as a growth hormone-releasing hormone analog. FDA labeling states that it stimulates the GRF receptor, which increases growth hormone secretion and leads to downstream IGF-1 effects.
What is tesamorelin FDA-approved for in the United States?
Current FDA labeling for EGRIFTA WR and EGRIFTA SV limits tesamorelin’s approved use to the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.
Is tesamorelin FDA-approved for MASLD or MASH?
No. The FDA labels reviewed here do not list MASLD or MASH as approved indications. The approved use is limited to HIV-associated lipodystrophy with excess abdominal fat.
Is tesamorelin a weight-loss drug?
No. Official labeling specifically states that tesamorelin is not indicated for weight management.
Why is tesamorelin being studied in liver-fat research?
Earlier research linked to NIH and Mass General in people living with HIV and NAFLD reported reductions in liver fat and less fibrosis progression with tesamorelin compared with placebo. Those findings help explain why it remains of investigational interest in liver-fat studies.
What does NCT07481734 describe?
Official ClinicalTrials.gov snippets describe NCT07481734 as a Phase II, randomized, double-blind, placebo-controlled study evaluating daily subcutaneous tesamorelin for liver-fat reduction. The record references MASLD or NAFLD, adults ages 18 to 75, standardized lifestyle counseling in both groups, and a primary MRI-PDFF endpoint at week 52.
Why is NCT07481734 a compliance-sensitive reference?
Because the official record snippet includes “Mock Study” in the title, lists Hudson Biotech as both sponsor and responsible party, and identifies a China site at Peking University Shenzhen Hospital. That means the record should be verified before being used as a live marketing proof point.
Does NCT07481734 use the same dose as the current labeled tesamorelin products?
Not based on the sources reviewed here. The NCT07481734 snippet describes tesamorelin 2 mg subcutaneously once daily, while current FDA labels list 1.28 mg once daily for EGRIFTA WR and 1.4 mg once daily for EGRIFTA SV. The labels also state that the marketed formulations are not substitutable.
What should sponsors or CROs prepare before requesting tesamorelin clinical research material?
At a minimum, teams should define the indication, protocol stage, target dose and formulation, comparator or placebo requirements, countries and sites, timeline, and the documentation needed for study startup. Providing that information early makes vendor discussions more precise and helps reduce avoidable delays.
Does this page describe commercial EGRIFTA distribution?
No. This draft is positioned around clinical trial and clinical research use, not commercial branded-drug distribution. Hudson Biotech should not claim commercial EGRIFTA supply unless that role has been verified and cleared for publication.
Who is this page for?
This page is intended for biotech and pharmaceutical sponsors, CROs, procurement teams, investigators, and research institutions evaluating tesamorelin in a clinical research or study-planning context.
Should Hudson Biotech use “tesamorelin peptide manufacturer USA” on this page?
Only if Hudson has verified its current U.S. legal entity and operating location. The client brief says USA-based, but that detail was not independently confirmed in this review.